septerna novo nordisk - Search News

News

Novo Nordisk Inks $2.2B Deal With Septerna

The Wall Street Journal on MSN · 1d

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

Seeking Alpha · 12h

Septerna: Deal With Novo Nordisk Is A Game Changer, While It Still Trades Well Below Net Cash

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

Reuters on MSN · 2d

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases that could be worth up to $2.

Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

15h

Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

17h

Novo Nordisk CEO Jorgensen to Leave After Fall in Share Price

Novo Nordisk A/S ousted Chief Executive Officer Lars Fruergaard Jorgensen as the drugmaker struggles with growing competition ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results